[go: up one dir, main page]

HUT77442A - 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUT77442A
HUT77442A HU9702043A HU9702043A HUT77442A HU T77442 A HUT77442 A HU T77442A HU 9702043 A HU9702043 A HU 9702043A HU 9702043 A HU9702043 A HU 9702043A HU T77442 A HUT77442 A HU T77442A
Authority
HU
Hungary
Prior art keywords
group
substituted
carboxyl
mono
salt
Prior art date
Application number
HU9702043A
Other languages
English (en)
Other versions
HU223945B1 (hu
Inventor
Mitsuo Fujii
Hiroshi Inami
Masamichi Okada
Shuichi Sakamoto
Masao Sasamata
Jun-Ichi Shishikura
Shin-Ichi Tsukamoto
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Publication of HUT77442A publication Critical patent/HUT77442A/hu
Publication of HU223945B1 publication Critical patent/HU223945B1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9702043A 1994-09-27 1995-09-25 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények HU223945B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23190894 1994-09-27
JP5948295 1995-03-17
PCT/JP1995/001922 WO1996010023A1 (fr) 1994-09-27 1995-09-25 Derive de 1,2,3,4-tetrahydroquinoxalindione

Publications (2)

Publication Number Publication Date
HUT77442A true HUT77442A (hu) 1998-04-28
HU223945B1 HU223945B1 (hu) 2005-03-29

Family

ID=26400527

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9702043A HU223945B1 (hu) 1994-09-27 1995-09-25 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények

Country Status (16)

Country Link
US (1) US6096743A (hu)
EP (1) EP0784054B1 (hu)
KR (1) KR100392151B1 (hu)
CN (1) CN1067387C (hu)
AT (1) ATE209644T1 (hu)
CA (1) CA2199468C (hu)
DE (1) DE69524246T2 (hu)
DK (1) DK0784054T3 (hu)
ES (1) ES2168383T3 (hu)
HU (1) HU223945B1 (hu)
MX (1) MX9702244A (hu)
PL (1) PL181532B1 (hu)
PT (1) PT784054E (hu)
RU (1) RU2149873C1 (hu)
UA (1) UA44283C2 (hu)
WO (1) WO1996010023A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057304A (en) * 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE19519979A1 (de) * 1995-05-24 1996-11-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
EP0980865B1 (en) * 1997-03-14 2003-11-26 Meiji Seika Kaisha Ltd. Physiologically active substance pf1191 and process for producing the same
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
PL344406A1 (en) * 1998-06-01 2001-11-05 Shionogi & Co Cyanoiminoquinoxaline derivatives
ATE324369T1 (de) 1999-02-15 2006-05-15 Eisai Co Ltd Heterodiazinon-derivate
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
US6709667B1 (en) 1999-08-23 2004-03-23 Conceptus, Inc. Deployment actuation system for intrafallopian contraception
ATE330941T1 (de) * 2000-01-24 2006-07-15 Neurosearch As Isatinderivate mit neurotropen aktivität
KR100869271B1 (ko) 2000-06-12 2008-11-18 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물 및 그의 용도
ATE440959T1 (de) * 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
CA2440284A1 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4200902B2 (ja) * 2002-03-29 2008-12-24 アステラス製薬株式会社 神経膠芽腫治療剤
JPWO2003087091A1 (ja) * 2002-04-17 2005-08-18 アステラス製薬株式会社 キノキサリンジオン誘導体無水物の新規結晶
WO2004002488A1 (ja) * 2002-06-28 2004-01-08 Yamanouchi Pharmaceutical Co., Ltd. 脳出血治療剤
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
US20060270709A1 (en) * 2005-04-04 2006-11-30 Eisai Co. Ltd. Dihydropyridine compounds and compositions for headaches
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
JP5183302B2 (ja) * 2007-05-29 2013-04-17 参天製薬株式会社 グルココルチコイド受容体結合活性を有する、スルホン酸エステル又はスルホン酸アミド構造を導入したフェニル基を置換基として有する新規1,2,3,4−テトラヒドロキノキサリン誘導体
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 nmda 수용체 길항물질
WO2010053757A1 (en) * 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
WO2020124090A1 (en) 2018-12-14 2020-06-18 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
US20240398775A1 (en) 2021-09-15 2024-12-05 University Of The Ryukyus Pharmaceutical composition for use in treating cognitive decline or for use in treating overweight or obesity
JPWO2023042888A1 (hu) 2021-09-15 2023-03-23

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007847A1 (en) * 1990-11-06 1992-05-14 Yamanouchi Pharmaceutical Co., Ltd. Fused pyrazine derivative
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH07165756A (ja) * 1993-12-14 1995-06-27 Yamanouchi Pharmaceut Co Ltd ヒドロキシキノキサリンジオン誘導体
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Also Published As

Publication number Publication date
PL181532B1 (pl) 2001-08-31
PL320059A1 (en) 1997-09-01
EP0784054B1 (en) 2001-11-28
RU2149873C1 (ru) 2000-05-27
EP0784054A1 (en) 1997-07-16
ES2168383T3 (es) 2002-06-16
CA2199468C (en) 2006-06-06
DE69524246D1 (de) 2002-01-10
DE69524246T2 (de) 2002-06-27
US6096743A (en) 2000-08-01
ATE209644T1 (de) 2001-12-15
WO1996010023A1 (fr) 1996-04-04
KR970706274A (ko) 1997-11-03
KR100392151B1 (ko) 2003-11-20
EP0784054A4 (en) 1998-01-07
AU684392B2 (en) 1997-12-11
CN1067387C (zh) 2001-06-20
CA2199468A1 (en) 1996-04-04
AU3533795A (en) 1996-04-19
UA44283C2 (uk) 2002-02-15
PT784054E (pt) 2002-05-31
HU223945B1 (hu) 2005-03-29
CN1168670A (zh) 1997-12-24
MX9702244A (es) 1997-06-28
DK0784054T3 (da) 2002-03-25

Similar Documents

Publication Publication Date Title
HUT77442A (hu) 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
AU6052594A (en) New heterocyclic compounds
CA2311742A1 (en) 6-amino-9-benzyl-8-hydroxypurine derivatives
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
EP0902007A4 (en) CHALCONE DERIVATIVES AND MEDICINES CONTAINING THEM
IL98872A0 (en) Pyrazolopyridine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
PL334915A1 (en) Pyrrolidine derivatives exhibiting phospholipase a2 inhibiting activity
IL101839A0 (en) Peptide compounds,processes for the preparation thereof,and pharmaceutical compositions containing the same
WO2001026629A3 (en) Neutral-cationic lipid for nucleic acid and drug delivery
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
GR3021143T3 (en) Imidazole derivatives and pharmaceutical compositions containing the same.
AU6820790A (en) Quinazoline derivatives and their preparation
GB9125970D0 (en) New compounds
AU536270B2 (en) Cytostatic iso cyanuric compositions
EP0420086A3 (en) Pyrimidoindole derivatives and processes for preparation thereof
AU7506591A (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050203

HPC4 Succession in title of patentee

Owner name: ASTELLAS PHARMA INC., JP

MM4A Lapse of definitive patent protection due to non-payment of fees